NDA 214985 · Idorsia
Quviviq
Daridorexant Hydrochloride · Oral · Orexin Receptor Antagonist
NovelCDER novel approval, Jan 7, 2022: To treat insomnia
Last checked: Nov 19, 2026Latest source record: Sep 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jan 7, 2022
Approved uses
3
Original approval plus efficacy supplements
Registered trials
49
6 Phase 3, 7 recruiting
FAERS reports
2,777
996 serious, 78 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 26, 2026.
QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies (14.1) ] . QUVIVIQ is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )
Mechanism: The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 30, 2024 Supplement 11 · Efficacy LabelLetter
- Sep 30, 2024 Supplement 10 · Efficacy LabelLetter
- Jan 7, 2022 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
2 products under this application
- QUVIVIQ · DARIDOREXANT HYDROCHLORIDE EQ 50MG BASE · TABLET, ORAL · Prescription
- QUVIVIQ · DARIDOREXANT HYDROCHLORIDE EQ 25MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Daridorexant" as an intervention, any sponsor and status, largest first.
- Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia SymptomsPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT07136415 · 1,000 participants (planned) · Start Feb 13, 2026 · Primary completion Feb 2031
Drug: Trazodone; Daridorexant · For: Menopausal Women; Insomnia
Sites: Boston, Massachusetts; Novi, Michigan; Winston-Salem, North Carolina · 5 sites in all
- Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia DisorderPivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03545191 · 930 participants · Start Jun 4, 2018 · Primary completion Jan 25, 2020
Drug: Daridorexant 25 mg; Daridorexant 50 mg · For: Insomnia Disorder
Sites: Anniston, Alabama; Birmingham, Alabama; Little Rock, Arkansas · 81 sites in all
- Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to SleepPivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03575104 · 924 participants · Start May 29, 2018 · Primary completion Apr 9, 2020
Drug: Daridorexant · For: Insomnia Disorder
Sites: Glendale, Arizona; Tucson, Arizona; Little Rock, Arkansas · 86 sites in all
- Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to SleepPivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03679884 · 804 participants · Start Oct 9, 2018 · Primary completion Feb 22, 2021
Drug: Daridorexant 10 mg; Daridorexant 25 mg and 2 more · For: Insomnia Disorder
Sites: Birmingham, Alabama; Glendale, Arizona; Tucson, Arizona · 106 sites in all
- Department of Defense PTSD Adaptive Platform Trial - Master ProtocolPivotal-lookingSuspended
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT05422612 · 800 participants (planned) · Start Nov 2, 2023 · Primary completion Jul 2028
Drug: Intervention A Fluoxetine Hydrochloride (HCl); Intervention A Placebo and 6 more · For: Post Traumatic Stress Disorder
Sites: Miami, Florida; Atlanta, Georgia; Tripler AMC, Hawaii · 9 sites in all
- Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia DisorderPivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT02839200 · 360 participants · Start Oct 4, 2016 · Primary completion Apr 12, 2017
Drug: ACT-541468 5 mg; ACT-541468 10 mg and 4 more · For: Insomnia Disorder
Sites: Santa Monica, California; Upland, California; Brandon, Florida · 35 sites in all
- A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the DayPivotal-lookingRecruiting
Idorsia Pharmaceuticals Ltd.Industry
NCT07843329 · 344 participants (planned) · Start Oct 28, 2026 · Primary completion Nov 22, 2027
Drug: Daridorexant; Placebo · For: Insomia Disorder
Sites: Little Rock, Arkansas; Lemon Grove, California; Pomona, California · 9 sites in all
- Daridorexant for Alzheimer Disease PreventionPivotal-lookingRecruiting
Douglas Mental Health University InstituteAcademic, hospital or other
NCT07213349 · 240 participants (planned) · Start Oct 14, 2025 · Primary completion Dec 2028
Drug: Daridorexant 50 mg; Placebo · For: Alzheimer Disease (AD)
Sites: Montreal, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective482
- insomnia327
- nightmare281
- somnolence183
- fatigue171
- headache168
- product availability issue148
- abnormal dreams137
- feeling abnormal124
- inappropriate schedule of product administration122
- suicidal ideation100
- dizziness98
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 505 |
| 2023 | 1,154 |
| 2024 | 217 |
| 2025 | 402 |
| 2026 | 497 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Quviviq (Daridorexant HCl)
2024 spending
$24.4M
Beneficiaries
12,891
46,269 claims
Per beneficiary
$1,891
$16.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $2,396,493 |
| 2023 | $16,342,719 |
| 2024 | $24,381,569 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Citrome L, et al. · Transl Psychiatry 2025 · Comparative Study, Network Meta-Analysis
- Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis.
Yue JL, Chang XW, Zheng JW, et al. · Sleep Med Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
Mignot E, Mayleben D, Fietze I, et al. · Lancet Neurol 2022 · Clinical Trial, Phase III, Multicenter Study
- Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
Kunz D, Dauvilliers Y, Benes H, et al. · CNS Drugs 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
Dauvilliers Y, Zammit G, Fietze I, et al. · Ann Neurol 2020 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Idorsia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.